Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea (ROSAPHOTOLASE)

• ClinicalTrials.gov Identifier: NCT03708263
• Recruitment Status: Not yet recruiting
• First Posted: October 17, 2018
• Last Update Posted: November 18, 2020
• Sponsor: University Hospital, Lille
• Collaborators: Institut National de la Santé Et de la Recherche Médicale, France; Medical Research Fund of the Tampere University Hospital, Finland
• Information provided by (Responsible Party): University Hospital, Lille

Study Description

Brief Summary:

Rosacea is a frequent dermatological condition, with a chronic and disturbing evolution that is characterized by redness, permanent erythema associated with telangiectasia (visible and permanent dilatation of the small vessels). It frequently affects men and women with fair skin and can have significant psycho-emotional consequences.

To counteract the unaesthetic appearance of redness and eliminate telangiectasia, the use of the laser is proposed to the patient.

This study is a single center prospective, randomized, controlled split face study to compare 532nm KTP laser versus 585 nm PLV Laser in terms of improvement of the symptoms in the treatment of Erythematotelangiectatic Rosacea 20 subjects will receive up to 3 laser treatments at day 0, month 2 and 4 and will be followed at month 6 and 12.

Condition or disease	Intervention/treatment	Phase
Erythematotelangiectatic Rosacea	Device: Excel V 532nm (KTP) green Laser; Device: PHOTOLASE PLV 585 nm yellow laser	Not Applicable

Detailed Description:

Adult male and female subjects 18 years of age or older will participate in the study after the objectives, methods, and potential risks of the study have been explained, and after they have signed the informed consent form.

Patients will come to the investigation center for a maximum of 6 visits.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Single-blinded, Monocentric, Randomized Pilot Study, to Evaluate the Yellow Laser PHOTOLASE PLV-585nm Versus the Reference Green Laser (KTP Excel V 532 nm) in the Treatment of Erythematotelangiectatic Rosacea
• Estimated Study Start Date: February 2021
• Estimated Primary Completion Date: February 2022
• Estimated Study Completion Date: February 2022

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 532nm KTP Laser; Cutera® Excel V 532 nm Application of light spots 5 to 7 mm for a pulse duration of 8 to 20 ms and a fluence of 7.4 to 10 J / cm2.	Device: Excel V 532nm (KTP) green Laser; Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
Experimental: 585 nm yellow laser; PHOTOLASE PLV 585 nm Application of light spots 1.4mm for a pulse duration of 10 to 100 ms and a fluence of 0 to 65 J / cm2.	Device: PHOTOLASE PLV 585 nm yellow laser; Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization

Outcome Measures

Primary Outcome Measures :

1. Degree of improvement in Erythematotelangiectatic Rosacea [ Time Frame: at Month 2 ]

   Measured, for each treatment arm, based on blinded physician assessment of subject photographs using the 7 points Telangiectasia Grading Score.

   (-1 = Aggravation of telangiectasia, 0 = no change, 1 = poor improvement (<25% decrease), 2 = intermediate improvement (25-50% decrease), 3 significant improvement (50-75% decrease), 4 = very significant improvement (75-99% decrease), 5 = complete improvement (100% decrease)

Secondary Outcome Measures :

1. Degree of improvement in Erythematotelangiectatic Rosacea evaluated by a blinded physician. [ Time Frame: at Month 4, 6,12 ]
   Measured, for each treatment arm, based on subject photographs using the 7 points Telangiectasia Grading Score
2. Measures of skin reaction for each treatment arm [ Time Frame: At baseline, At Month 2, At Month 4 (if realized) ]
   Measured with a 4 points scale : no reaction, low, moderate and severe reaction
3. Pain evaluation during each treatment [ Time Frame: At baseline, At Month 2, At Month 4 (if realized) ]
   Mosby Pain Rating Scale for each treatment arm
4. Change in lesion skin color in each treatment arm [ Time Frame: At Baseline, at Month 2, 4, 6,12 ]
   Measured with Chroma-Meter CR400 (Konica Minolta), Mean a* value
5. Subject satisfaction level [ Time Frame: At Month 6,12 ]
   Comparison of each treatment arm using Subject Overall Evolution Scale
6. Change in Life Quality [ Time Frame: At Selection, at Baseline, at Month 2, 4 (if realized), 6,12 ]
   Comparison of Dermatology Life Quality Index
7. Practitioner's opinion [ Time Frame: At baseline, At Month 2, At Month 4 (if realized) ]
   Comparison, for each treatment arm, of comfort of use, practicality, duration of treatment
8. Adverse Events [ Time Frame: At Baseline, At Month 2, 4, 6,12 ]
   Incidence and severity of adverse effects, for each treatment arm, during the study period

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Fitzpatrick Skin Type I - III
• Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment and during the entire course of the study.
• Clinical diagnosis of Erythematotelangiectatic Rosacea stade II
• Homogeneous extend and staining telangiectasia in each half face
• Patient never treated with laser for Rosacea
• Patient doesn't wish to use systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area.
• Patient agreeing to have limited exposure to the sun and use of a protective screen (index 50 or higher) every day of the study and throughout its duration if it takes place from May to September.
• Patient must be able to read, understand and sign the Informed Consent Form
• Patient able to adhere to the program of visits of the study and the other imperatives of the protocol
• Patient accepting to have photographs taken on the face
• Quality of social insurance or social security entitlement

Exclusion Criteria:

• Pregnant and/or breastfeeding woman or childbearing age without effective contraception
• Alcohol abuse assessed at the discretion of the investigator
• History of prior laser or light based procedures for any other pathology for the face within 6 months of study participation Fitzpatrick Type IV à VI
• Systemic use of isotretinoin in the 6 months prior to inclusion in the study.
• Topical use of retinoids and / or corticosteroids in the 4 weeks prior to inclusion in the study.
• Patient under photo sensitization treatment
• Patient suffering from significant concurrent illness such as type 1 diabetes, cardiovascular disease, uncontrolled hypertension, neurological disease, lupus erythematosus, scleroderma.
• Patient subject to hypertrophic or abnormal scarring
• Patient presenting or having a malignant tumor or skin cancer in the area to be treated.
• Having a known anticoagulative condition or taking prescription anticoagulation medications.
• Participation to another clinical study involving a laser or drug within three months of inclusion in the study.
• Smoker or former smoker in the 12 months prior to inclusion in the study.
• Patient with excessive tattoos in the area to be treated and / or wishing to tattoo the treated area during the study.
• Patient treated for cancer by chemotherapy or radiotherapy
• Patient with hyper or hypo pigmentation
• Patient unable to understand protocol or give consent
• Legal incapacity (persons deprived of their liberty or under guardianship or curatorship)
• Patient in emergency or in detention
• Clinical follow-up impossible for psychological, family matters, social or geographical reasons

Contacts and Locations

Contacts

Contact: Cyril MAIRE, MD; (0)3 20 44 48 68 ext +33; cyril.maire@chru-lille.fr

Sponsors and Collaborators

University Hospital, Lille

Institut National de la Santé Et de la Recherche Médicale, France

Medical Research Fund of the Tampere University Hospital, Finland

Investigators

• Principal Investigator: Cyril MAIRE, MD; University Hospital, Lille
• Study Director: Serge MORDON, Pr; Institut National de la Santé Et de la Recherche Médicale, France

More Information

• Responsible Party: University Hospital, Lille
• ClinicalTrials.gov Identifier: NCT03708263
• Other Study ID Numbers: 2017_57; 2018-A01904-51 ( Other Identifier: ID-RCB number, ANSM )
• First Posted: October 17, 2018
• Last Update Posted: November 18, 2020
• Last Verified: September 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital, Lille:

532 nm green Laser; 585 nm yellow laser; rosacea; telangiectasis score; skin disease

Additional relevant MeSH terms:

Rosacea; Skin Diseases